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Abstract
Background: Epstein-Barr virus (EBV) has a close association with various types of human lymphomas. Animal
models are essential to elucidate the pathogenesis of human EBV-associated lymphomas. The aim of the present
study is to evaluate the association between human IgG concentration and EBV-associated lymphoma
development in huPBL/SCID mice.
Methods: Human peripheral blood lymphocytes (hu-PBL) from EBV-seropositive donors were inoculated
intraperitoneally into SCID mouse. Immunohistochemical staining was used to examine differentiated antigens of
tumor cells. EBV infection of the induced tumors was detected by in situ hybridization. IgG concentrations in the
serums of 12 SCID mice were measured by unidirectional immunodiffusion assay.
Results: 21 out of 29 mice developed tumors in their body. Immunohistochemical staining showed that all
induced tumors were LCA (leukocyte common antigen) positive, B-cell markers (CD20, CD79a) positive, and T-cell
markers (both CD3 and CD45RO) negative. The tumors can be diagnosed as human B-cell lymphomas by these
morphological and immunohistochemical features. In situ hybridization exhibited resultant tumor cells had EBV
encoded small RNA-1 (EBER-1). Human-derived IgG could be found in the serum from SCID mice on the 15
th day
following hu-PBL transplantation, and IgG levels increased with the tumor development in 6 hu-PBL/SCID chimeras.
Conclusions: Intraperitoneal transfer of hu-PBLs from EBV+ donors to SCID mice leads to high human IgG levels in
mouse serum and B cell lymphomas. Our findings suggest that increasing levels of human-derived IgG in
peripheral blood from hu-PBL/SCID mice could be used to monitor EBV-related human B-cell lymphoma
development in experimental animals.
Background
Epstein-Barr virus (EBV) is a ubiquitous human herpes
virus that persists in most human bodies as a lifelong
latent infection in host lymphocytes after a primary viral
encounter, and it has been confirmed to be the etiologi-
cal factor of infectious mononucleosis [1,2]. More
important, EBV, which may be one of human tumor
viruses [3], has a close association with human lym-
phoma and nasopharyngeal carcinoma [4-6]. Although
EBV can transform human lymphocytes and squamous
epithelia in vitro, it is impossible to conduct controllable
investigation on human body. It is also a difficult pro-
blem to induce neoplasm with EBV in animal body. Up
to date, no study about infection and oncogenicity of
EBV has been done with an ideal animal model.
Animal models of lymphoma are essential to elucidate
the pathogenesis of human EBV-associated lymphomas.
Severe combined immunodeficient (SCID) mouse
(homozygous C.B.-17 scid/scid) expresses a truncated
form of the catalytic subunit of the DNA-dependent
protein kinase and is unable to properly rearrange the
Ig and TCR genes. The ensuing severe combined immu-
nodeficiency endows these mice with the capacity to
accept xenografts. Because SCID mice lack functional T
or B lymphocytes, they can be engrafted with function-
ing human hematolymphoid cells to create human/SCID
chimeras [7,8]. In immunosuppressed individuals, such
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B cells may lead to lymphoproliferative disease [9].
Injection of human peripheral blood lymphocytes (hu-
PBLs) or hematopoietic stem cells from EBV-positive
donors into SCID mice induces human lymphoprolifera-
tive disease in the humanized SCID recipients [10,11].
This xenochimeric human-mouse model can be used to
elucidate the mechanisms of EBV-specific lymphoma-
genesis and to assess novel therapeutic approaches. The
aim of the present study is to detect molecular biomar-
kers of the EBV-induced lymphomas in hu-PBL/SCID
mice and to measure serum IgG levels in hu-PBL/SCID
chimeras.
Materials and methods
Construction of hu-PBL/SCID chimeras
SCID(C.B.-17scid/scid) mice were bought from Labora-
tory Animal Center of Science Academy in China, 6 to
8 weeks old, 18 ± 2.43 g in weight, male or female. All
mice were bred in micro-isolator cages in a specific
pathogen-free (SPF) environment. Animal studies were
approved by Institutional Animal Care and Use Com-
mittee (IACUC) of Chinese Academy of Sciences.
Fresh peripheral venous blood was collected from 12
healthy adult donors by 300 ml per one, and PBLs were
separated from heparinized peripheral blood by isopyc-
nic centrifugation on Ficoll-Hypaque. The EBV immune
status of donors was assessed by using a standard
E L I S Af o rt h ep r e s e n c eo fas e r u mI g Aa n t i - E B V - v i r a l -
capsid-antigen(IgA/VCA). Hu-PBLs from EBV-seroposi-
tive donors were inoculated intraperitoneally into 29
SCID mice by 1 × 10
8 PBLs resuspended in 1 ml RPMI-
1640 medium per mouse, such mice are hereafter
referred to as hu/SCID chimeras.
Assay for human IgG of mouse serum
12 mice were bled from a tail vein on days 3, 7, 15, 22,
33, and 46 post hu-PBLs transplantation, 10-20 μlb l o o d
for each mouse every time; serum samples were stored at
-80°C until use. The concentrations of human IgG in
mouse serums were assessed by unidirectional immuno-
diffusion assay. Briefly, serum samples were diluted (1:5),
a n dl o a d e d1 0μl/well on the mouse anti-human IgG
immunodiffusion plate. The plate was incubated in a wet
box at 37°C for 24 h. Then the plate was taken out to
have the diameter of the precipitation loop measured.
The values of IgG were calculated with the diameter-con-
tent contrast table prepared by the manufacturer.
Animal observation, anatomical and histopathological
examination
SCID mice were bred in cages separately, with the
abnormities of weight, behavior, fur, abdomen and
respiration monitored. If animals were sick, they would
be killed and exposed to excess-ethyl-ether, then autop-
sied. In other SCID mice, follow-up was extended to
135 days. The position of tumor formation and thorax-
celiac viscera were under particular observation.
Examining the thorax -celiac cavity, mediastinum and
other main organs of mice, such as heart, lung, brain,
liver, spleen, kidney, lymphnodes, and etc. Observing
the size, shape, color, section and invasion of tumor
with naked eye. Each tumor mass was divided into 2
samples: one was immediately frozen at -80°C for DNA
analysis; the other part was fixed in 10% neutralized for-
malin, embedded in paraffin and sectioned at 4 μmf o r
histopathology observation and immunohistochemical
examination.
Immunohistochemical staining of the induced tumor
Tumors were fixed in 10% neutral formalin, embedded
in paraffin and cut into 4 μm sections for further study.
Immunohistochemical stains were performed to assess
differentiated antigens of tumor cells, a panel of mono-
clonal antibodies against lymphocytes (LCA, CD45), B
cells (L26/CD20, CD79a) and T cells (CD45RO, CD3)
(purchased from Maxin Co., San Francisco, LA) respec-
tively according to the manufacturer’s protocol. Briefly,
endogenous peroxidase was quenched with 0.3% hydro-
gen peroxide. Before the application of the primary anti-
body, nonspecific binding was blocked with normal
non-immune serum, and tissue slides were incubated
with each diluted antibody at 4°C overnight. Bound anti-
body was detected with biotin-conjugated secondary
antibody followed by streptavidin-peroxidase and diami-
nobenzidine (DAB) color reagent. The slides were coun-
ter-stained with hematoxylin. A case was regarded as
positive if more than 5% of the malignant cells were
stained with the antibody, although in practice most
positive cases had 20% or more of their cells marked.
Human-specific Alu detection by PCR
DNA was extracted from tumor tissues as described in
protocol. Alu PCR was conducted under the following
conditions: 95°C predenaturation for 5 min, and then 30
cycles of denaturation at 94°C for 1 min, annealing at
57°C for 1 min and extension at 72°C for 1 min. Primers
(sense: 5’-CAC CTG TAA TCC CAG CAG TTT-3’,
anti-sense: 5’-CGC GAT CTC GGC TCA CTG CA-3’)
were used to amplify a 221 bp sequence for human-spe-
cific Alu.
In situ hybridization of EBV infection
The synthetic oligonucleotide EBER1 probe (sequence:
5’-CTC CTC CCT AGC AAA ACC CTC AGG ACG
GCG-3’) [10] was end-labeled with digoxigenin by tail-
ing with terminal transferase. The labeling reaction was
set up according to the manufacturer’sp r o t o c o l
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situ hybridization using EBER1 probe was carried out as
follows. Briefly, the glass slides were pretreated with 2%
APES. 4-μm tissue slices of the induced tumors were
heated at 70°C for 1 h, and deparaffinaged in xylene,
then digested with 0.5% μg/ml proteinase K at 37°C for
10 min, and washed in water. The labeled probes were
diluted to a concentration of 100 ng/ml in hybridization
medium [25% deionized formamide, 4 × SSC (sodium
citrate, sodium chloride), 50 mmol/L NaH2PO4/
Na2HPO4, 1 mmol/L EDTA, 5 × Denhart’s, 1 mg/ml
ssDNA], and then spotted on to the tissue slices, which
were covered with a coverslip. Both DNA probe and tar-
get RNA in tissue slices were simultaneously denatured
at 70°C for 8 min. Then the sections were hybridized at
37°C for 4 h or overnight. The non-specific or unbound
probes were removed by two post-hybridization washes
as follows: 2 × SSC, 0.1 × SSC, each for 10 min at room
temperature. The slices were blocked with 2% normal
goat serum at room temperature for 20 min, incubated
with anti-Digoxigenin antibody at 37°C for 30 min, and
then washed 3 times. NBT/NCIP was used as the chro-
mogen. Counter-staining was done to enhance visualiza-
tion with nuclear fast red.
Results
The EBV-related neoplasms in the SCID mice were solid
masses. 21 out of 29 mice (72%) developed tumors in
their body. By autopsy, some were round-shaped nodes
(Figure 1A), with distinct boundary and no envelope;
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Figure 1 Morphology and immunological marker examination of EBV-associated tumors in hu-PBL/SCID mice. (A) Fresh tumor tissue out
of SCID mouse showed gray-white and gray-red node, size 17 × 11 × 8 mm. (B) The histopathological type of the induced-tumors was diffuse
large cell lymphoma (HE × 400). (C) Positive staining of LCA located on the membrane of the tumor cells (SP × 400). (D) Immunohistochemistry
revealed that positive staining of B-cell marker (CD20, L26) located on the membrane of tumor cells (SP × 400). (E) Negative staining of T-cell
marker (CD45RO) of the tumor cells (SP × 400). (F) Negative staining of T-cell marker (CD3) of the tumor cells (SP × 400).
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organs. The diameters of tumors were about 0.5-3.6 cm,
and the cuts displayed pale and gray-red. Moreover, loci
of necrosis could be observed in the center of larger
tumors. Under microscope, tumor cells diffusely
arranged with rare sparse interstitial fibers and tiny ves-
sels. The tumors were dominated by large cleaved and
non-cleaved cells (Figure 1B), with a few large and
diverse immunoblasts and plasmacytoid lymphocytes
and a few megalocytes as well. Karyokinesis could be
easily observed and nucleoli were distinct in the tumor
c e l l s .T h et u m o r si nt h ea b d o m i n a lc a v i t yo fm i c eo f t e n
invaded into kidney, liver, pancreas, mesentery; and
those in the midiastinum invaded into striated-muscles
of posterior thoracic wall. All of the pathological charac-
ters revealed that the induced-tumor was highly malig-
nant non-Hodgkin’s lymphoma (NHL).
Immunohistochemical staining showed that all
induced tumors were LCA (leukocyte common antigen)
positive (Figure 1C), B-cell marker (CD20, CD79a) posi-
tive (Figure 1D), and T-cell markers (both CD3 and
CD45RO) negative (Figure 1E, F). By these morphologi-
cal and immunohistochemical features, those tumors
can be diagnosed as human B-cell lymphomas. Further-
more, Alu-PCR showed that all of tumor tissues con-
tained 221 bp Alu sequence (Figure 2). It confirmed
that the induced tumors in hu-PBL/SCID mice were
derived from human, but not from mouse.
In biopsy tissue, localization of EBER transcripts by in
situ hybridization remains the gold standard for identify-
ing latent infection of EBV. The in situ hybridization
signal of EBER1 probe was very intense with a diffuse
pattern of staining confined to the nucleus (sparing the
nucleus) in all cases (Figure 3). Notably, almost all
morphologically malignant cells exhibited a positive sig-
nal with the EBER1 probe, while the normal host tissue
adjacent to tumor cells showed negative.
In the 12 mice whose IgG was examined, human
serum IgG could be found in 6 SCID mice on day 15
after the engraftment of hu-PBLs and the IgG concen-
trations increased with the prolongation of the experi-
ment (Figure 4), and then visible tumors developed.
Marked elevations of human serum IgG levels in hu-
PBL/SCID mice are associated with EBV-related lym-
phoma development. Human serum IgG levels from hu-
PBL/SCID mice can be considered as a useful index of
prediction for oncogenesis and tumor development. In
contrast, IgG could not be detected both in the 3 mice
with micro-lymphoproliferative lesions only and in the
other 3 mice with no tumors during the experimental
course. Additionally, our data showed human IgG con-
centrations in the serum of each of hu-PBL/SCID chi-
meras were also positively related to the serum IgG
levels from different donors.
Discussion
With the development of human organ transplantation
and the increase of AIDS cases in recent years, both
lymphoproliferative disease (LPD) in the immunocom-
promised patients and its relationship with EBV have
become increasingly followed with interest [1]. Clini-
cally, almost all post-transplantation lymphomas are
associated with EBV infection [12,13]. Post-transplant
lymphoprolifertive disorder (PT-LPD) is a syndrome of
uncontrolled lymphoid growth in the immunosup-
pressed transplant patient. In the patients with PT-LPD,
the incidence varies from 0.5% after bone marrow trans-
plantation to 12% after heart-lung transplantation. PT-
LPD remains so far a complication with a high morbid-
ity and mortality. EBV is associated with posttransplant
lymphoproliferative disease (PTLD), which is a leading
cause of cancer death in recipients of transplants. On
the other hand, investigations for AIDS-related lympho-
mas show that about 50-80% of those tumors are con-
cerned with EBV [14]. The vast majority of AIDS-NHL
belongs to three kinds of high-grade B-cell lymphomas:
Burkitt’s lymphoma, immunoblastic lymphoma, and
large-cell lymphoma [15]. Although there are some dif-
ferences between this immunodeficiency-associated lym-
phoproliferative disorders, they share several common
features: a tendency to present in extranodal sites, rapid
clinical progression when untreated, diffuse large cell
histology, B-cell origin and association with the EBV
[16]. The occurrence of lymphoma needs the activation,
proliferation and transform of B-cell, as well as the
development of malignant phenotype. The present
experiment showed that B-cell lymphoma in the hu-
PBL/SCID chimeras was similar to EBV-related
221bp 221bp
Figure 2 PCR amplified 221 bp products of human-specific Alu
sequence of the EBV-induced tumors in SCID mice. M: DNA
marker, P: human peripheral blood lymphocytes as positive control,
N: murine liver tissue as negative control, T: tumor biopsy tissues.
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could further indicate that immunodeficiency of animal
or human body is an essential condition for the
tumorigenesis.
EBV is a herpesvirus associated with approximately 1%
of tumours worldwide. EBV is the epitome of B lympho-
tropic viruses, but the spectrum of tumours associated
with EBV extends to various types of human malignan-
cies and carcinomas [1]. Ubiquitous EBV infection in
humans implies that most individuals carry EBV-
infected cells. Therefore, mere detection of the virus in
individuals with a tumour is not sufficient for establish-
ing a causal relationship between both events. Currently
there is no in vivo model that can adequately recapitu-
late EBV infection and its association with B-cell
lymphomas. In this experiment, we can observe the
development of EBV-related lymphoma in the SCID
mice engrafted with hu-PBLs from EBV-seropositive
donors. 72% of mice (21/29) developed tumors in EBV-
positive hu-PBL/SCID chimeras. The tumors possess
solid, aggressive and fatal features, and belong to high
malignant NHL in histopathology. Both Alu-gene detec-
tion and immune marker examination showed that the
induced-tumors were derived from human B-cell, and
the tumor cells contained EBV-encoded small RNA
(EBER). We have successfully induced human B-cell
lymphomas in the body of hu-PBL/SCID chimeras. An
in vivo model of human CD20+ B-lymphoma was estab-
lished in SCID mice with huPBLs transplantation from
EBV-seropositive donors.
Our present experiment showed that intraperitoneal
transfer of hu-PBLs from EBV+ donors to SCID mice
could generate human-derived B cell lymphomas. But it
is necessary for us to monitor EBV-associated human B-
cell lymphoma development in the body of SCID mice.
IgG is an immunoglobulin secreted by plasmocyte when
mature B cells are differentiated into plasmocytes by anti-
gen stimulation. It is reported that human-derived IgG
can be used to assess whether immune function of SCID
mouse with hu-PBL engraftment is reconstructed [17,18]
and that antigen stimulation promotes human secondary
IgG responses in hu-PBL/SCID mouse [19,20]. Interest-
ingly, a significantly positive relationship exists between
the appearance of human IgG and tumorigenesis of B-
cell lymphoma in the findings of our present study.
Those SCID mice in which human serum IgG continu-
ously increased would finally developed visible tumors in
their bodies. In the mice without human serum IgG dur-
ing all the experimental phases, no tumor or only micro-
lymphaproliferative lesions was identified with micro-
scope. From our data, human serum IgG concentrations
in hu-PBL/SCID chimeras were also related to the serum
IgG levels from original donors. However, the IgG level
AB AB
Figure 3 Detection of EBER in the induced lymphoma of SCID mice. (A) Diffuse large cell lymphomas invaded into pancreatic tissue (arrow)
of SCID mouse by microscopic observation (HE stain × 400). (B) Positive signals of EBER-1 were located in the nuclei of all tumor cells by in situ
hybridization, whereas pancreatic epithelial cells (arrow) of SCID mouse were negative (×400).
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Figure 4 Human IgG levels in the serums of 6 tumor-bearing
mice at different time points. The concentration of human IgG in
the serum of each of SCID mice increased gradually on days 7, 15,
22, 33 and 46 after hu-PBL transplantation.
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Page 5 of 6from a donor was not related to the development of
tumors. It meant that all B-lymphocytes that produce dif-
ferent IgG levels from various donors had the same
potential to develop lymphomas if activated by EBV.
Moreover, it is of importance and practice for us to repli-
cate the tumor model in the future. So we can predict
the tumorigenesis by detecting human serum IgG levels
from hu-PBL/SCID mice during the experimental phases.
More importantly, it can give us a dependable serum
marker if we want to test therapeutic intervention on the
EBV-induced lymphomas.
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